Research programme: cancer immunotherapies - Incysus

Latest Information Update: 20 Apr 2018

Price : ^*

* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

Originator Incysus
Class Antineoplastics; Cell therapies; T lymphocyte cell therapies
Mechanism of Action Immunostimulants; Lymphocyte replacements; T lymphocyte replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Preclinical Glioblastoma; Haematological malignancies; Solid tumours

Most Recent Events

21 Mar 2018 Preclinical trials in Glioblastoma in USA (Parenteral), prior to March 2018
20 Mar 2018 Incysus plans a phase I trial for Solid tumours (Combination therapy) in 2018
20 Mar 2018 Pharmacodynamics data from a preclinical trial in Glioblastoma multiforme released by University of Alabama at Birmingham

Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Login with a username/password associated to an account with a valid subscription
Contact your organization’s admin about adding this content to your AdisInsight subscription
Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.